# CMAtlas: a comprehensive DNA methylation atlas for exploring epigenetic alterations in 34 human cancer types

**Authors:** Mengni Liu, Lizhen Jiang, Luowanyue Zhang, Tianjian Chen, Xingzhe Wang, Yuan Liang, Xianping Shi, Jian Ren, Yueyuan Zheng

PMC · DOI: 10.1093/bioinformatics/btag022 · Bioinformatics · 2026-01-14

## TL;DR

CMAtlas is a new platform that maps DNA methylation changes in 34 cancer types, integrating multi-omics data to support precision oncology and drug discovery.

## Contribution

The novel contribution is a comprehensive DNA methylation atlas with deep multi-omics integration across 34 cancer types and 13,753 samples.

## Key findings

- CMAtlas identified 830,725 tumor-specific DMEs and 1,480,098 DMRs across diverse cancer types.
- The platform shows high cross-platform consistency and strong concordance between tumor tissues and cell lines.
- Prognostic methylation patterns in colorectal cancer driver genes were identified using CMAtlas.

## Abstract

Aberrant DNA methylation is a fundamental epigenetic hallmark of cancer. However, existing resources often lack technological diversity and comprehensive cancer coverage. Furthermore, most platforms fail to achieve deep multi-omics integration and tend to ignore cancer-type-specific methylation features, limiting their utility in precision oncology and drug discovery.

We developed Cancer Methylation Atlas (CMAtlas), a comprehensive platform integrating 13 753 samples across 34 cancer types. By applying technology-tailored pipelines to data from various profiling technologies, we identified 830 725 tumor-specific differentially methylated elements (DMEs) and 1 480 098 differentially methylated regions (DMRs), alongside 1 154 256 cancer-type-specific DMEs and 329 154 DMRs. The platform demonstrates high cross-platform consistency and strong concordance between tumor tissues and cell lines, ensuring the robustness of our findings. All DMEs and DMRs are annotated with multi-omics data (RNA expression, somatic mutations, and chromatin accessibility) and clinical relevance (survival associations and cell-free DNA profiling). We further demonstrate the utility of CMAtlas by identifying prognostic aberrant methylation in colorectal cancer driver genes.

CMAtlas is freely accessible at {{https://cmatlas.renlab.cn/}}. The platform offers an intuitive web interface supporting gene-centric and cancer-centric queries, alongside customizable analysis modules designed to facilitate user-specific research needs.

## Linked entities

- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, TCF4 (transcription factor 4) [NCBI Gene 6925] {aka CDG2T, E2-2, FCD2, FECD3, ITF-2, ITF2}, MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase) [NCBI Gene 4249] {aka GNT-V, GNT-VA, MGAT5A, glcNAc-T V}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}
- **Diseases:** CMAtlas (MESH:D009369), stomach adenocarcinoma (MESH:D013274), esophageal adenocarcinoma (MESH:D000230), DM (MESH:D012734), colorectal cancer (MESH:D015179), colorectal carcinogenesis (MESH:D063646), GI cancer (MESH:D005770), DMEs (MESH:C565217), cholangiocarcinoma (MESH:D018281), liver metastasis (MESH:D009362), COAD (MESH:D029424)
- **Chemicals:** DME (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12881830/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12881830/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12881830/full.md

---
Source: https://tomesphere.com/paper/PMC12881830